PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11264347-4	2001	Thus, in vivo anti-CD154 monoclonal antibody (MAb) treatment inhibited MAIDS symptoms in LP-BM5-infected wild-type mice when either a short course of anti-CD154 MAb treatment was started on the day of infection or a course was initiated 3 to 4 weeks after LP-BM5 administration, after disease was established.	N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide	92-95	CD40 ligand	Mus musculus	19-24	
9499800-3	1998	Prompted by previous reports showing that the onset of MAIDS is dependent on the presence of both CD4+ T and B cells, we have previously shown that anti-gp39/CD40 ligand mAb (anti-CD40L mAb) treatment of LP-BM5-infected mice is effective in inhibiting the induction of MAIDS when a short course of anti-CD40L mAb treatment was started on the same day as LP-BM5 administration.	N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide	207-210	CD40 ligand	Mus musculus	158-169	
9499800-3	1998	Prompted by previous reports showing that the onset of MAIDS is dependent on the presence of both CD4+ T and B cells, we have previously shown that anti-gp39/CD40 ligand mAb (anti-CD40L mAb) treatment of LP-BM5-infected mice is effective in inhibiting the induction of MAIDS when a short course of anti-CD40L mAb treatment was started on the same day as LP-BM5 administration.	N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide	207-210	CD40 ligand	Mus musculus	180-185